Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Inclusion Criteria:

* Histologic confirmation of squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix including FIGO (International Federation of Gynecologists and Obstetricians) stage IB to IVA with or without pelvic adenopathy.
* No evidence of para-aortic or distant metastases. Must have evaluable disease.
* Zubrod Performance Status 0-2 or Karnofsky Performance Status \> 60
* Laboratory values must be as follows:

White blood cell count: \> 3,000/mm3,Absolute granulocyte count: \> 1,500/mm3, Hemoglobin \> 8.0 g/dl, Platelets: \> 100,000/mm3, Serum creatinine: \< 2.5 mg/dl, Serum calcium: \< 1.3 x institutional upper normal limit,Hepatic criteria as follows: Total Bilirubin \< ULN for the institution,

* Signed study-specific informed consent p
* Age \> 18 years.
* Peripheral neuropathy must be \< grade 1.

Exclusion Criteria:

* Prior or simultaneous malignancies (other than skin cancer) unless disease-free
* Medical illness preventing the use of taxane-based chemotherapy.
* Carcinoma of the cervix with the following histology: melanoma, sarcoma, small carcinoid, glassy cell, clear cell, and adenoid cystic.
* Previous or current medical or psychiatric illness that would prevent informed consent
* Patients known to be infected with HIV or a history of AIDS are excluded.
* Prior surgery for carcinoma of the cervix other than a biopsy.
* Patients with para-aortic disease.
* Previous pelvic radiation therapy or systemic chemotherapy is not permitted.
* Women who are pregnant or breast-feeding are excluded from this study.
* Previous history of hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80 must be excluded.